EUVIMEDEUVIMED entdecken
Crossref

Impact of Programmed Death Ligand 1 Expression on Outcomes in Stage I-II Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma

Kotaro Murakami, Yoshihisa Shimada, Masatsugu Hamaji, Keiji Yamanashi, Yohei Kawaguchi, Yujin Kudo, Hidenao Kayawake, Yojiro Yutaka, Hiroshi Date, Norihiko Ikeda

Clinical Lung Cancer · 2026-05 · 27 (4) · 141-148.e4

DOI: 10.1016/j.cllc.2026.03.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2026-05. Verfasst von Kotaro Murakami und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan. Electronic address: km1985@tokyo-med.ac.jp. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung, B7-H1 Antigen. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: We aimed to investigate the clinicopathological characteristics and prognostic significance of programmed death ligand 1 (PD-L1) expression in patients with pathological stage I-II epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) undergoing surgical resection. PATIENTS AND METHODS: Patients with EGFR-mutant LUAD who underwent complete surgical resection between 2017 and 2019 at 2 institutions were retrospectively analyzed. PD-L1 expression was assessed using the tumor proportion score (TPS) with a cutoff of ≥ 1%. Clinical outcomes, including recurrence-free survival (RFS) and overall survival, were examined based on PD-L1 expression. Propensity score matching was used to reduce confounding, and multivariate analyses were performed to identify independent prognostic factors. Additionally, progression-free survival (PFS) was assessed based on PD-L1 expression to investigate the efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) after postoperative recurrence. RESULTS: Among 243 patients identified, those classified as PD-L1-positive (TPS ≥ 1%) exhibited significantly shorter 5-year RFS than PD-L1-negative patients (81.3% vs. 95.3%, P < .001). Male sex, advanced pathological T factor, tumor differentiation, and visceral pleural invasion or lymphovascular invasion were identified as significant predictors of recurrence. Although the population was small, the PFS for PD-L1-positive patients who received EGFR-TKIs was 21.4 months, which was significantly longer than the 7.6 months for PD-L1-negative patients. CONCLUSIONS: PD-L1 expression is a useful biomarker for predicting postoperative recurrence in patients with EGFR-mutant LUAD, and the therapeutic effect of EGFR-TKIs is sufficient even in PD-L1-positive patients. These findings support the current treatment guidelines and highlight the need for further studies to explore the role of PD-L1 in postoperative management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinoma of LungB7-H1 AntigenHumansMaleFemaleErbB ReceptorsRetrospective StudiesPrognosisMutationNeoplasm StagingAgedMiddle AgedBiomarkers, TumorSurvival RateProtein Kinase InhibitorsNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Early-stagePostoperative recurrencePrognostic biomarkerRecurrence-free survivalSurvival

Substanzen

ErbB ReceptorsB7-H1 AntigenCD274 protein, humanEGFR protein, humanBiomarkers, TumorProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan. Electronic address: km1985@tokyo-med.ac.jp.
  • Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Surgery, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Zitieren

APA

Murakami, K., Shimada, Y., Hamaji, M., Yamanashi, K., Kawaguchi, Y., Kudo, Y., Kayawake, H., Yutaka, Y., Date, H., & Ikeda, N. (2026). Impact of Programmed Death Ligand 1 Expression on Outcomes in Stage I-II Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma. Clinical Lung Cancer, 27(4), 141-148.e4. https://doi.org/10.1016/j.cllc.2026.03.013

Vancouver

Murakami K, Shimada Y, Hamaji M, Yamanashi K, Kawaguchi Y, Kudo Y, et al. Impact of Programmed Death Ligand 1 Expression on Outcomes in Stage I-II Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma. Clinical Lung Cancer. 2026;27(4):141-148.e4. doi:10.1016/j.cllc.2026.03.013

BibTeX
@article{Murakami2026,
  author = {Murakami, Kotaro and Shimada, Yoshihisa and Hamaji, Masatsugu and Yamanashi, Keiji and Kawaguchi, Yohei and Kudo, Yujin and Kayawake, Hidenao and Yutaka, Yojiro and Date, Hiroshi and Ikeda, Norihiko},
  title = {Impact of Programmed Death Ligand 1 Expression on Outcomes in Stage I-II Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma},
  journal = {Clinical Lung Cancer},
  year = {2026},
  volume = {27},
  number = {4},
  pages = {141--148.e4},
  doi = {10.1016/j.cllc.2026.03.013}
}
Kostenlos starten →